Verona Pharma initiated with a Buy at Roth MKM - Markets Insider

5 days ago · Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma with a Buy rating and $68 price target The firm says its investment thesis is driven by …

$68
OFF

Verona Pharma Initiated With A Buy At Roth MKM - Markets Insider

2 weeks from now

5 days ago · Roth MKM analyst Boobalan Pachaiyappan initiated coverage of Verona Pharma with a Buy rating and $68 price target The firm says its investment thesis is driven by …

businessinsider.com

$68.00
OFF

Verona Pharma Plc (NASDAQ:VRNA) Given Consensus …

2 weeks from now

4 days ago · Roth Mkm initiated coverage on shares of Verona Pharma in a research note on Friday. They issued a "buy" rating and a $68.00 target price for the company. HC Wainwright …

marketbeat.com

$68
OFF

Stock Analyst Ratings: Upgrades And Downgrades - Investing.com

2 weeks from now

Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The... By …

investing.com

$60
OFF

Roth Initiates Verona Pharma At Buy - MarketScreener

2 weeks from now

5 days ago · -- Verona Pharma has an average rating of buy and mean price target of $60, according to analysts polled by FactSet. Price: 44.59, Change: -1.61, Percent Change: -3.48 ...

marketscreener.com

$37.00
OFF

Buy Rating Affirmed For Verona Pharma: Breakthrough COPD …

2 weeks from now

Aug 14, 2024 · Canaccord Genuity analyst Edward Nash maintained a Buy rating on Verona Pharma (VRNA – Research Report) yesterday and set a price target of $37.00.. Edward Nash …

businessinsider.com

$400
OFF

Roth/MKM Avvia La Copertura Del Titolo Verona Pharma Con Rating …

2 weeks from now

4 days ago · La posizione finanziaria di Verona Pharma è anche un fattore chiave nel rating ottimistico della società. Con una solida riserva di cassa di circa $400 milioni alla fine del …

investing.com

$68
OFF

Roth MKM Initiates Coverage On Verona Pharma With Buy Rating, …

2 weeks from now

5 days ago · Roth MKM analyst Boobalan Pachaiyappan initiates coverage on Verona Pharma (NASDAQ:VRNA) with a Buy rating and announces Price Target of $68. Roth MKM analyst …

sahmcapital.com

FAQs about Verona Pharma initiated with a Buy at Roth MKM - Markets Insider Coupon?

Is Verona Pharma a good stock to buy?

The firm issued a buy rating and a $68.00 price objective on the stock. Several other equities analysts have also commented on the stock. Wells Fargo & Company raised their target price on shares of Verona Pharma from $64.00 to $74.00 and gave the company an “overweight” rating in a report on Wednesday, January 8th. ...

What was Verona Pharma's stock price on January 1st 2024?

Verona Pharma's stock was trading at $19.88 on January 1st, 2024. Since then, VRNA shares have increased by 114.7% and is now trading at $42.68. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Monday, November, 4th. ...

Who owns Verona Pharma?

Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. Diversify Advisory Services LLC bought a new position in Verona Pharma during the third quarter worth $169,000. ...

Should you buy Verona Pharma vs GSK?

Selvaraju recognizes the strategic fit between Verona Pharma and GSK, particularly considering Verona’s British origins and GSK’s strong background in respiratory treatments. Moreover, the anticipation of FDA approval for Verona’s ensifentrine as a maintenance therapy for COPD by mid-2024 bolsters the rationale for the Buy rating. ...

Does Mirae own Verona Pharma?

Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock worth $75,000 after purchasing an additional 529 shares during the period. ...

How many EPs will Verona Pharma post?

Equities research analysts forecast that Verona Pharma will post -2.11 EPS for the current year. In related news, CFO Mark W. Hahn sold 12,936 shares of Verona Pharma stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $5.00, for a total transaction of $64,680.00. ...